Feds Fund InforMedix in HIV Adherence Program; NIH Provides Funding to use the Med-eMonitor System to Monitor Medication and Care Plan Adherence in San Francisco HIV Patients.

ROCKVILLE, Md. -- InforMedix Holdings, Inc. (OTCBB:IFMX), creating a new technology platform that enables patients to manage chronic illnesses at home, today announced plans to use its patented Med-eMonitor(TM) System with HIV-positive patients in San Francisco.

The Company said it has received a commitment for $149,000 in Federal funds for the program, which will be conducted by San Francisco General Hospital and led by David R. Bangsberg, M.D., an internationally renowned expert on medical adherence.

According to Dr. Bangsberg "Without near-perfect adherence, complex anti-retroviral cocktails simply do not work, yet trying to improve adherence to HIV therapy today is like trying to monitor thousands of patients with high blood pressure - but with no equipment."

Dr. Bangsberg went on to say, "Historically, the electronic medication monitor has not penetrated the routine clinical practice setting because it only monitors one medication at a time and precludes the use of pill box organizers that may improve adherence. However, by incorporating electronic monitoring within a pill box design a system can monitor individuals' medication adherence in real time, and can calculate the risk of virologic failure, which is communicated via an Internet connection to a clinical care team that is capable of intervening on adherence before the development of resistance. InforMedix has combined a good product with a good team."

The device prompts users when to take medication by sounding a chime. A compartment is opened to take the pill, with information displayed on an LCD screen that describes the pill and informs the patient about dosage, and includes special instructions such as "take with food." Patient education is a key part of the program, and the device asks questions about such things as side effects or symptoms. All patient interactions are automatically recorded with a time and date stamp, and patient data is automatically downloaded to a secure website for evaluation by physicians, clinical teams and care managers.

Between 1.03 and 1.185 million people in the US are living with HIV, with an additional 40,000 becoming infected each year, at a cost to the US health care system of approximately $50,000-$75,000 per year per patient, which results in total costs of $50 billion to $75 billion in total annual costs. Average adherence to HIV antiretroviral therapy is under 70%, and 20-33% of HIV-positive patients will miss at least one of their doses over any given 3-day period. And yet, just a 10% difference in adherence between individuals is associated with a doubling of viral load, and a 21% increase in the risk of progression to full-blown AIDS. The Federally funded 50 patient, 90 day HIV Program using the Med-eMonitor System may demonstrate improved patient medication adherence and reduce HIV viral load, thereby improving treatment outcomes and reducing costs.

According to Dr. Bruce A. Kehr, M.D, Chairman and Chief Executive Officer of InforMedix, "We believe the Med-eMonitor can make an enormous difference in improving the quality of life for HIV-positive patients, and dramatically lower the cost of caring for these patients borne by every major health care payor in the United States and around the world. We are very excited to have the support of Federal funding, the San Francisco General Hospital and the most distinguished and committed leadership of Dr. Bangsberg in supporting the treatment of HIV patient medication adherence, and providing independent quantitative data to validate widespread adoption of the device."

The Med-eMonitor System leverages InforMedix' strong intellectual property consisting of 15 issued patents and 12 patents pending. Previous studies have validated its use in dramatically improving medication and care plan adherence, which results in lowering the cost of care for patients with Diabetes, Congestive Heart Failure, and Schizophrenia.

About InforMedix

InforMedix has developed the Med-eMonitor System as The Medication Adherence Solution for disease management and clinical drug trials markets. InforMedix has integrated a portable patient-interactive monitoring device, hardware, software and networked communications system to enable disease management programs, pharmaceutical and biotechnology companies, and medical researchers to efficiently monitor and manage patients' medication and care plan adherence, clinical response, and drug safety. The Med-eMonitor is specifically designed to improve patient medication compliance and care plan adherence in disease management and clinical drug trials programs. In a recent program for diabetes patients, the Med-eMonitor System improved mean medication adherence rates to over 92% compared to a baseline medication adherence rate of 40%, and also reduced Hemoglobin A1c (HbA1c) levels by an average of 18.5% in a 3 month period. The Med-eMonitor System leverages InforMedix's strong intellectual property consisting of 15 issued patents and 12 patents pending. InforMedix's patents have been cited as prior art by patent examiners in over 150 other issued patents. To find out more about InforMedix, Inc. (OTCBB:IFMX), visit our website at www.informedix.com.

This report contains "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and are subject to the safe harbors created thereby. These forward-looking statements include the Med-eMonitor System may demonstrate improved patient medication adherence and reduce HIV viral load, thereby improving treatment outcomes and reducing costs; and Dr. Kehr's quotes in the 7th paragraph. References made to the discussion of the risk factors are detailed in the Company's filings with the Securities and Exchange Commission, including our Annual Report on Form 10-KSB for the year ended December 31, 2005, our prospectus dated March 28, 2005 and our other filings with the U.S. Securities and Exchange Commission. These forward-looking statements are made only as of the date hereof, and we disclaim any obligation to update or revise the information contained in any such forward-looking statements, whether as a result of new information, future events or otherwise.